Search

Your search keyword '"Kim Rathana"' showing total 170 results

Search Constraints

Start Over You searched for: Author "Kim Rathana" Remove constraint Author: "Kim Rathana"
170 results on '"Kim Rathana"'

Search Results

1. Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients

2. Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia

3. Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

5. Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation

6. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study

7. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition

8. Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia

9. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

10. Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL

12. Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML

13. Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 Study.

14. A multiparametric niche-like drug screening platform in acute myeloid leukemia

15. Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy

16. Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease

17. Interleukin-7 receptor α mutational activation can initiate precursor B-cell acute lymphoblastic leukemia

18. Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination

20. P319: IL7-RECEPTOR EXPRESSION IS FREQUENT IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND PREDICTS SENSITIVITY TO JAK-INHIBITION

21. P315: TP53 ALTERATIONS AND MRD REFINE PROGNOSIS OF ADULT KMT2A-REARRANGED B-ALL

22. UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia

23. IL7-receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK-inhibition

24. Supplementary Figures S1-S10 from Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis

25. Supplementary Tables S1-S11 from Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis

26. Data from Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis

27. Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis.

28. Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis

29. Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experience

30. Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from PreleukemicTP53-Mutant Clonal Hematopoiesis

31. 3041 – THE ROLE OF CLONAL HEMATOPOIESIS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA

32. Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study

33. Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study

34. Clonal evolution in hereditary thrombocytosis with MPL T487A mutation

36. Les lésions cutanées sweetoïdes du syndrome VEXAS sont dues à une infiltration myéloïde de cellules clonales mutées UBA1

37. Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2

38. Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial

39. Clonal Hematopoiesis Driven By MDM4 Amplification Defines a Canonical Route Towards Secondary MDS/AML in Fanconi Anemia Patients

40. UBA1 Variations in Neutrophilic Dermatosis Skin Lesions of Patients With VEXAS Syndrome

41. UBTFtandem duplications define a distinct subtype of adult de novo acute myeloid leukemia

42. Minimal residual disease quantification in ovarian tissue collected from patients in complete remission of acute leukemia

43. Ikaros deficiency is associated with aggressive BCR-ABL1 B cell precursor acute lymphoblastic leukemia independent of the lineage and developmental origin

44. MDS-029: Prevalence of VEXAS Syndrome in MDS/CMML Patients with Systemic Inflammatory and Auto-Immune Disease

45. Poster: MDS-029: Prevalence of VEXAS Syndrome in MDS/CMML Patients with Systemic Inflammatory and Auto-Immune Disease

46. Exploring the Heterogeneity of Response to Blinatumomab in High-Risk Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: An Analysis from the QUEST Sub-Study of the Graall-2014/B Trial

47. The Splicing-Associated Network PAK1-Clk-SRRM1 Is a Critical Vulnerability to Overcome Chemoresistance in Acute Myeloid Leukemia

48. Outcome and clinicophenotypical features of acute lymphoblastic leukemia/lymphoblastic lymphoma with cutaneous involvement: A multicenter case series

49. KMT2A-ARHGEF12, a Therapy Related Fusion with Dismal Prognosis.

50. Caractéristiques cliniques, pathologiques et moléculaires des myelodysplasia cutis

Catalog

Books, media, physical & digital resources